Lazard Asset Management LLC Purchases Shares of 4,677 BrainsWay Ltd. (NASDAQ:BWAY)

Lazard Asset Management LLC acquired a new position in shares of BrainsWay Ltd. (NASDAQ:BWAY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 4,677 shares of the company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Phoenix Financial Ltd. lifted its position in BrainsWay by 100.8% during the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company’s stock worth $4,552,000 after buying an additional 242,366 shares during the period. ARK Investment Management LLC acquired a new position in shares of BrainsWay during the 4th quarter valued at about $1,656,000. MYDA Advisors LLC increased its stake in shares of BrainsWay by 100.2% during the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock valued at $1,133,000 after acquiring an additional 60,100 shares during the last quarter. Zuckerman Investment Group LLC lifted its holdings in shares of BrainsWay by 346.4% during the 4th quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company’s stock worth $667,000 after acquiring an additional 51,991 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of BrainsWay by 61.9% in the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock worth $226,000 after acquiring an additional 9,149 shares during the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

BrainsWay Trading Up 2.9%

Shares of BrainsWay stock opened at $10.73 on Tuesday. The business’s fifty day moving average price is $9.18 and its 200 day moving average price is $9.71. BrainsWay Ltd. has a twelve month low of $5.25 and a twelve month high of $11.79. The stock has a market capitalization of $202.50 million, a P/E ratio of 107.31 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. The business had revenue of $11.54 million for the quarter, compared to analyst estimates of $11.45 million. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. As a group, sell-side analysts predict that BrainsWay Ltd. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.